DB-1419 for Advanced Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial requires an adequate treatment washout period (time without taking certain medications) before the first dose of the study treatment, so you may need to stop some of your current medications. It's best to discuss this with the trial team to understand which medications are affected.
What safety data exists for DB-1419 in humans?
What is the purpose of this trial?
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Research Team
Lily Hu
Principal Investigator
DualityBio Inc.
Eligibility Criteria
This trial is for adults over 18 with advanced or metastatic solid tumors that have worsened after standard treatments, or when no standard treatment exists. Participants must have a measurable lesion, be in good physical condition (ECOG score of 0-1), and expect to live at least three more months. They should not have had certain heart conditions, prior B7-H3 therapy, significant QTcF prolongation, active autoimmune diseases requiring recent treatment, HIV infection, symptomatic CNS metastases without stability post-treatment, severe lung diseases or infections needing IV drugs within the last two weeks.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive DB-1419 at various dose levels to assess safety, tolerability, and preliminary antitumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
Treatment Details
Interventions
- DB-1419
Find a Clinic Near You
Who Is Running the Clinical Trial?
DualityBio Inc.
Lead Sponsor